| Project/Area Number |
26640106
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Tumor therapeutics
|
|---|
| Research Institution | Juntendo University |
|---|
Principal Investigator |
Hosomi Osamu 順天堂大学, スポーツ健康科学部, 客員教授 (30134274)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
SASAKI Hiraku 順天堂大学, スポーツ健康科学部, 准教授 (20384969)
|
|---|
| Project Period (FY) |
2014-04-01 – 2016-03-31
|
| Project Status |
Completed (Fiscal Year 2015)
|
| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2015: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2014: ¥2,730,000 (Direct Cost: ¥2,100,000、Indirect Cost: ¥630,000)
|
|---|
| Keywords | オリゴ糖 / 多様性 / がん細胞 / 抗がん剤 / アポトーシス / グルコサミン / 副作用 / apoptosis / 高転移性 / QOL |
|---|
| Outline of Final Research Achievements |
We have developed oligosaccharide (Galα1-6GlcNH2) which suppresses proliferation of a human leukemia cell hard and have advanced a study for the effect of the oligosaccharide by using mice. If MelNH2 is a safe anticancer drug for body and has scarcely any side effect like a usual anticancer drug, we expect it can contribute widely to society.
Elucidation of the mechanism which a cancer cell takes MelNH2 in is left. However we find that MelNH2 causes chromatin aggregation of a cancer cell, and that release and cohesion of a calcium ion from ER. Thus we expect that these affects of MelNH2 to cancer cell induces apoptosis.We observed over expressions of metallothionein genes of K562 cell by a DNA microarray and RT-PCR, indicating that MelNH2 cytotoxicity against cancer cell exceeds the limit to which a cancer cell can correspond. Moreover, the binding reaction of hnRNP-A1 and MelNH2 was identified, indicating that a splicing activity of hnRNP-A1 is inhibited by MelNH2.
|
